I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

[1]  Danny F. Martinez,et al.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.

[2]  S. Gambhir,et al.  Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody. , 2014, Biomaterials.

[3]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[4]  T. Waldmann,et al.  Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[6]  M. Tsuchiya,et al.  Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization , 2010, Anti-cancer drugs.

[7]  J. Furuse,et al.  Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma , 2014, Cancer science.

[8]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Tetsuji Yamaguchi,et al.  High preoperative levels of serum glypican‐3 containing N‐terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy , 2015, International journal of cancer.

[10]  J. Humm,et al.  124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET , 2011, The Journal of Nuclear Medicine.

[11]  S. Larson,et al.  Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors , 1995, European Journal of Nuclear Medicine.

[12]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Stroebel,et al.  Erythrocyte volume, plasma volume, and lean body mass in adult men and women. , 1969, Blood.

[14]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[15]  P. Philip,et al.  First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[16]  Serge K. Lyashchenko,et al.  A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.

[17]  S. Larson,et al.  Cyclotron production and potential clinical application of Iodine-124 labeled radiotracers , 2001 .

[18]  Serge K. Lyashchenko,et al.  Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT , 2016, The Journal of Nuclear Medicine.

[19]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[20]  S. Larson,et al.  Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer , 2013, Nuclear medicine communications.

[21]  S. Larson,et al.  Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[22]  C Cobelli,et al.  SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.

[23]  Serge K. Lyashchenko,et al.  89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  J. Humm,et al.  Copper-64 trastuzumab PET imaging: a reproducibility study. , 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[25]  S. Larson,et al.  Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  S. Selleck,et al.  Glypicans: proteoglycans with a surprise. , 2001, The Journal of clinical investigation.

[27]  S. Larson,et al.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  S. Larson,et al.  Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) , 2017, Cancer Chemotherapy and Pharmacology.

[29]  H. Aburatani,et al.  Human Liver Cancer Glypican 3 Antibody as a Potential Antitumor Agent for − Anti , 2008 .

[30]  S. Larson,et al.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Richard O'Kennedy,et al.  Coming-of-Age of Antibodies in Cancer Therapeutics. , 2016, Trends in pharmacological sciences.

[32]  J. Humm,et al.  PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  P. L. Jager,et al.  Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.

[34]  Mitchell Ho,et al.  Glypican‐3 antibodies: A new therapeutic target for liver cancer , 2014, FEBS letters.

[35]  J. Humm,et al.  124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.

[36]  Steven P. Larson,et al.  Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Mitchell Ho,et al.  Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. , 2015, Molecular pharmaceutics.

[38]  K. Chijiiwa,et al.  Prognostic significance of circumferential cell surface immunoreactivity of glypican‐3 in hepatocellular carcinoma , 2011, Liver international : official journal of the International Association for the Study of the Liver.